All In Biotech

Free tool

FAERS Monitor: Horizant

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022399 or its brand name (Horizant, Gabapentin Enacarbil). Reports on generic versions are filed under their own applications.

Reports

2,844

Serious

1,590

56% of reports

Hospitalization

394

Death reported

700

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • toxicity to various agents594
  • completed suicide277
  • drug ineffective217
  • off label use187
  • drug abuse138
  • dizziness126
  • somnolence125
  • nausea122
  • insomnia116
  • cardio-respiratory arrest110
  • headache110
  • fatigue99
  • feeling abnormal95
  • pain89
  • dyspnoea88

Reports by year received

View as table
YearReports
201132
2012104
201359
201435
201592
2016206
2017340
2018352
2019442
2020308
2021212
2022293
2023119
202489
2025100
202661

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,315 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
toxicity to various agentsSignal59426.124.314,401
completed suicideSignal27724.722.06,269
cardio-respiratory arrestSignal11019.516.21,911
drug abuseSignal13812.310.41,422
somnolenceSignal1254.63.9351
insomniaSignal1163.22.7178
feeling abnormalSignal952.92.4120
dizziness1261.91.651
off label use1871.61.441
headache1101.31.17
drug ineffective2171.21.19
dyspnoea881.10.92
nausea1221.11.02
pain891.10.90
fatigue990.90.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.